Cargando…

Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements

PURPOSE: To report on the commissioning and clinical validation of the first commercially available independent Monte Carlo (MC) three‐dimensional (3D) dose calculation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA). METHODS: The independent dose calculation (IDC) by SciMoCa® (...

Descripción completa

Detalles Bibliográficos
Autores principales: Milder, Maaike T. W., Alber, Markus, Söhn, Matthias, Hoogeman, Mischa S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700940/
https://www.ncbi.nlm.nih.gov/pubmed/33103343
http://dx.doi.org/10.1002/acm2.13046
_version_ 1783616388348248064
author Milder, Maaike T. W.
Alber, Markus
Söhn, Matthias
Hoogeman, Mischa S.
author_facet Milder, Maaike T. W.
Alber, Markus
Söhn, Matthias
Hoogeman, Mischa S.
author_sort Milder, Maaike T. W.
collection PubMed
description PURPOSE: To report on the commissioning and clinical validation of the first commercially available independent Monte Carlo (MC) three‐dimensional (3D) dose calculation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA). METHODS: The independent dose calculation (IDC) by SciMoCa® (Scientific RT, Munich, Germany) was validated based on water measurements of output factors and dose profiles (unshielded diode, field‐size dependent corrections). A set of 84 patient‐specific quality assurance (QA) measurements for multi‐leaf collimator (MLC) plans, using an Octavius two‐dimensional SRS1000 array (PTW, Freiburg, Germany), was compared to results of respective calculations. Statistical process control (SPC) was used to detect plans outside action levels. RESULTS: Of all output factors for the three collimator systems of the CyberKnife, 99% agreed within 2% and 81% within 1%, with a maximum deviation of 3.2% for a 5‐mm fixed cone. The profiles were compared using a one‐dimensional gamma evaluation with 2% dose difference and 0.5 mm distance‐to‐agreement (Γ(2,0.5)). The off‐centre ratios showed an average pass rate >99% (92–100%). The agreement of the depth dose profiles depended on field size, with lowest pass rates for the smallest MLC field sizes. The average depth dose pass rate was 88% (35–99%). The IDCs showed a Γ(2,1) pass rate of 98%. Statistical process control detected six plans outside tolerance levels in the measurements, all of which could be attributed the measurement setup. Independent dose calculations showed problems in five plans, all due to differences in the algorithm between TPS and IDC. Based on these results changes were made in the class solution for treatment plans. CONCLUSION: The first commercially available MC 3D dose IDC was successfully commissioned and validated for the CyberKnife and replaced all routine patient‐specific QA measurements in our clinic.
format Online
Article
Text
id pubmed-7700940
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77009402020-12-03 Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements Milder, Maaike T. W. Alber, Markus Söhn, Matthias Hoogeman, Mischa S. J Appl Clin Med Phys Technical Notes PURPOSE: To report on the commissioning and clinical validation of the first commercially available independent Monte Carlo (MC) three‐dimensional (3D) dose calculation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA). METHODS: The independent dose calculation (IDC) by SciMoCa® (Scientific RT, Munich, Germany) was validated based on water measurements of output factors and dose profiles (unshielded diode, field‐size dependent corrections). A set of 84 patient‐specific quality assurance (QA) measurements for multi‐leaf collimator (MLC) plans, using an Octavius two‐dimensional SRS1000 array (PTW, Freiburg, Germany), was compared to results of respective calculations. Statistical process control (SPC) was used to detect plans outside action levels. RESULTS: Of all output factors for the three collimator systems of the CyberKnife, 99% agreed within 2% and 81% within 1%, with a maximum deviation of 3.2% for a 5‐mm fixed cone. The profiles were compared using a one‐dimensional gamma evaluation with 2% dose difference and 0.5 mm distance‐to‐agreement (Γ(2,0.5)). The off‐centre ratios showed an average pass rate >99% (92–100%). The agreement of the depth dose profiles depended on field size, with lowest pass rates for the smallest MLC field sizes. The average depth dose pass rate was 88% (35–99%). The IDCs showed a Γ(2,1) pass rate of 98%. Statistical process control detected six plans outside tolerance levels in the measurements, all of which could be attributed the measurement setup. Independent dose calculations showed problems in five plans, all due to differences in the algorithm between TPS and IDC. Based on these results changes were made in the class solution for treatment plans. CONCLUSION: The first commercially available MC 3D dose IDC was successfully commissioned and validated for the CyberKnife and replaced all routine patient‐specific QA measurements in our clinic. John Wiley and Sons Inc. 2020-10-25 /pmc/articles/PMC7700940/ /pubmed/33103343 http://dx.doi.org/10.1002/acm2.13046 Text en © 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Technical Notes
Milder, Maaike T. W.
Alber, Markus
Söhn, Matthias
Hoogeman, Mischa S.
Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements
title Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements
title_full Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements
title_fullStr Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements
title_full_unstemmed Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements
title_short Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient‐specific QA measurements
title_sort commissioning and clinical implementation of the first commercial independent monte carlo 3d dose calculation to replace cyberknife m6™ patient‐specific qa measurements
topic Technical Notes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700940/
https://www.ncbi.nlm.nih.gov/pubmed/33103343
http://dx.doi.org/10.1002/acm2.13046
work_keys_str_mv AT mildermaaiketw commissioningandclinicalimplementationofthefirstcommercialindependentmontecarlo3ddosecalculationtoreplacecyberknifem6patientspecificqameasurements
AT albermarkus commissioningandclinicalimplementationofthefirstcommercialindependentmontecarlo3ddosecalculationtoreplacecyberknifem6patientspecificqameasurements
AT sohnmatthias commissioningandclinicalimplementationofthefirstcommercialindependentmontecarlo3ddosecalculationtoreplacecyberknifem6patientspecificqameasurements
AT hoogemanmischas commissioningandclinicalimplementationofthefirstcommercialindependentmontecarlo3ddosecalculationtoreplacecyberknifem6patientspecificqameasurements